Artificial intelligence-based predictive model for relapse in acute myeloid leukemia patients following haploidentical hematopoietic cell transplantation.

Background And Objectives: Relapse is one of the most critical causes of transplant failure in patients with acute myeloid leukemia (AML) receiving haploidentical-related donor (HID) hematopoietic stem cell transplantation (HSCT). We aimed to develop an artificial intelligence (AI)-based predictive model for post-transplant relapse in patients with AML receiving HID HSCT.

Methods: This study included patients with consecutive AML (aged ≥ 12 years) receiving HID HSCT in complete remission (CR).

Leukemia stem cells for relapse prediction in AML patients receiving allografts: long-term follow-up of a prospective study.

In this study, we explored the ability of leukemia stem cell (LSC)-based method and traditional multiparameter flow cytometry (MFC) assay to predict leukemia relapse after long-term follow-up. 360 AML patients who received allografts between July 2018 and November 2019 were prospectively enrolled. Patients with positive measurable residual disease (MRD) based on CD34CD38cocktail LSCs (≥0.

Clinical Characteristics and Outcomes of Influenza-Associated Late-Onset Severe Pneumonia After Allogeneic Hematopoietic Stem Cell Transplantation.

Background: Late-onset severe pneumonia (LOSP) is one of the most important causes of mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The influenza virus is a frequent viral pathogen in patients receiving allo-HSCT, accounting for at least 30% of all respiratory viral infections. We aimed to identify the clinical characteristics and outcomes of influenza-associated LOSP after allo-HSCT.

Peritransplant lysine methyltransferase 2a-rearranged measurable residual disease dynamics as a prognostic marker in adult acute myeloid leukemia.

Background: This study examined the impact of measurable residual disease (MRD) dynamics in adults with lysine methyltransferase 2a rearrangement (KMT2Ar) in acute myeloid leukemia (AML) during the peritransplant period (before and early after allogeneic hematopoietic stem cell transplantation [HSCT]).

Methods: This study involved 144 adult patients with AML with KMT2Ar who underwent HSCT between 2015 and 2024. Patients were enrolled if they survived without relapse for at least 3 months post-HSCT.

Incidence, Risk Factors, and Impact on Transplant Outcomes of Cytokine Release Syndrome After Infusion of Haploidentical Stem Cells With Anti-Thymocyte Globulin.

Background: Cytokine release syndrome (CRS) after graft infusion under anti-thymocyte globulin (ATG)-based haploidentical (haplo)-hematopoietic stem cell transplantation is unclear.

Objective: The purpose of this study was to explore the clinical implications of CRS after graft infusion under ATG-based haplo-SCT.

Study Design: We retrospectively analyzed the data of 259 patients who underwent haplo-SCT, graded CRS, and evaluated transplant outcomes.

Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Allogeneic haematopoietic cell transplantation (HCT) is a potentially curative therapy for peripheral T-cell lymphoma; however, to date, there are no standardised and detailed guidelines for its application. To address gaps in clinical practice, the European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonisation and Guidelines Committee convened an international expert meeting in Lille (France) on Sept 30 and Oct 1, 2024. EBMT performed funding acquisition.

PD-1 inhibitor in patients with minimal residual disease who failed donor lymphocyte infusion or interferon after allogeneic haematopoietic stem cell transplantation.

This study aimed to evaluate the efficacy and safety of programmed death receptor 1 (PD-1) antibody in patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) with minimal residual disease (MRD) after allogeneic haematopoietic stem cell transplantation (allo-HSCT). Six patients were retrospectively reviewed in this study, and all had failed prior treatment (donor lymphocyte infusion or interferon) before PD-1 antibody administration. Among these 6 patients, two received PD-1 alone while four received PD-1 plus azacitidine.

Investigation Into the Pathogenesis of Type 2 Cardiorenal Syndrome via the ROS-TRPM2 Signaling Axis.

Background: Type 2 cardiorenal syndrome (CRS) is a complex disease characterized by the interplay between the heart and kidneys. The pathophysiology of type 2 CRS involves multiple molecular signaling pathways. Transient receptor potential melastatin 2 (TRPM2) is a reactive oxygen species (ROS)-sensitive and non-selective calcium-permeable cation channel, which plays a regulatory role in intracellular Ca homeostasis.

The outcomes of second haploidentical donor transplantation for graft failure in patients with severe aplastic anaemia.

This study aimed to evaluate the outcomes of second haploidentical hematopoietic stem cell transplantation (HID-HSCT) for patients with severe aplastic anaemia (SAA) who experienced graft failure. Twenty-one SAA patients with graft failure after first allogeneic (allo-) HSCT were enrolled, including 6 (28.6%) with poor graft function and 15 (71.

A novel and safe protocol for patients with severe comorbidity who undergo haploidentical hematopoietic stem cell transplantation: A single-center prospective study.

Background And Objectives: Haploidentical stem cell transplantation (haplo-HSCT) has demonstrated promising results in patients without severe comorbidities. There is also an increasing need for haplo-HSCT in patients with severe comorbidities. However, the high risk of treatment-related mortality (TRM) hindered its extensive application.

Transplantation Related Mortality Did Not Show Significant Differences in Patients Aged Above 55 Years With Hematological Malignancies Receiving Allogeneic Hematopoietic Stem Cell Transplantation in a Real-World Study.

Transplantation related mortality (TRM) remains an issue, particularly in older patients with hematological malignancies. In order to assess the TRM and the feasibility of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in older patients, we collected data from a total of 251 patients aged 55-70 years with acute hematological malignancies who received allo-HSCT from April 19, 2011 to June 28, 2022 in our hospital. With the median follow-up of 637 days, the cumulative incidence of TRM for patients above 55 years on Day 100, 1 year, and 2 years was 6.

Comparison of outcomes between haploidentical and matched related donors for chronic myelomonocytic leukemia: A multicenter real-world study.

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative strategy for patients with chronic myelomonocytic leukemia (CMML). However, few reports have investigated the outcomes of patients receiving haploidentical HSCT. To this end, we included 117 patients with haploidentical donors (HID) and 75 patients with matched related donors (MRD) from 28 centers across China to explore the prognostic impact of different transplantation modalities.

Prognostic impact of dynamic changes of type I melanoma antigen gene proteins CT7 () transcripts in multiple myeloma.

Type I melanoma antigen gene proteins CT7 (), a cancer-testis (CT) gene, correlated with clinical parameters at diagnosis of multiple myeloma (MM). We first analyzed single-cell ribonucleic acid sequencing data from public databases to evaluate the expression of in MM patients and showed that is highly and specifically expressed in the MM cells. We then interrogated data from 216 consecutive cases with transcripts by quantitative real-time polymerase chain reaction longitudinally monitored in our center.

Safety, effectiveness and pharmacokinetics of high-dose propylene glycol-free melphalan (EVOMELA) with a prolonged infusion as myeloablative conditioning in Chinese multiple myeloma patients undergoing autologous stem cell transplantation: A prospective phase iv study.

BackgroundMelphalan formulated with modified cyclodextrin (β-cyclodextrin sulfobutyl ether sodium [BSES]) is widely used before autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM) because of its favorable solubility and stability versus conventional melphalan, but the efficacy and safety data on Chinese patients with MM who subsequently underwent ASCT are still limited.MethodsIn this prospective, open-label, non-randomized, interventional study, a total of 67 MM patients who were eligible for ASCT were enrolled and assigned to receive 200 mg/m of Melphalan in two divided doses of 100 mg/m on Days -3 and -2 before ASCT on Day 0. We evaluated the efficacy, safety and pharmacokinetics (PK) of a prolonged infusion of high-dose BSES-melphalan as the conditioning treatment in the patients.

G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Severe Aplastic Anemia Patients.

Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) continues to be a cornerstone in the treatment of severe aplastic anemia (SAA). The advancement of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) has broadened therapeutic possibilities, particularly for patients lacking fully human leukocyte antigen (HLA)-matched donors. However, it still remains unclear which type of graft source is better for SAA patients underwent haplo-HSCT.

CD34-selected stem cell boost was an effective treatment for refractory poor hematopoietic reconstitution after haploidentical hematopoietic stem cell transplantation.

Background: Poor hematopoietic reconstitution (PHR), especially poor graft function (PGF) and prolonged isolated thrombocytopenia (PT), is a life-threatening complication after allo- hematopoietic stem cell transplantation (HSCT). Currently, almost no studies have analyzed CD34+-selected stem cells "boost" (SCB) after haplo-HSCT. Hence, in this study, we focused specifically on refractory PHR after haplo-HSCT.

Metabolic adaptability and nutrient scavenging in : insights from ingestion pathway-deficient mutants.

Unlabelled: The obligate intracellular parasite replicates within a specialized compartment called the parasitophorous vacuole (PV). Recent work showed that despite living within a PV, endocytoses proteins from the cytosol of infected host cells via a so-called ingestion pathway. The ingestion pathway is initiated by dense granule protein GRA14, which binds host endosomal sorting complex required for transport (ESCRT) machinery to bud vesicles into the lumen of the PV.

Allogeneic versus autologous hematopoietic stem cell transplantation for adult T-lymphoblastic lymphoma: A real-world multicenter analysis in China.

Both allogeneic hematopoietic stem cell transplantation (allo-HSCT) and autologous HSCT (ASCT) are important consolidation therapies for T-lymphoblastic lymphoma (T-LBL). In this multicenter, real-world study, we aimed to compare the clinical outcomes between ASCT and allo-HSCT in adult T-LBL patients. 163 Ann Arbor stage III or IV T-LBL patients (>16 years) who achieved complete or partial response after induction chemotherapies and received HSCT across 11 transplant centers were enrolled.

6-Gingerol Inhibits Ferroptosis in Endothelial Cells in Atherosclerosis by Activating the NRF2/HO-1 Pathway.

Targeting endothelial cell ferroptosis is a potential approach for the treatment of atherosclerosis (AS). 6-Gingerol (6-Gin) is an active substance in ginger that is beneficial for improving AS. We conducted this study to explore whether 6-Gin mediated AS progression by regulating ferroptosis of endothelial cells.

Outcomes and prognostic factors associated with relapse after haploidentical stem cell transplantation for paediatric T-cell acute lymphoblastic leukaemia.

The outcomes are poor for paediatric patients with T-cell acute lymphoblastic leukaemia (T-ALL) who relapse after haematopoietic stem cell transplantation (HSCT). However, studies focusing on paediatric patients with T-ALL following haploidentical HSCT (haplo-HSCT) are limited. We retrospectively identified a consecutive cohort comprising of 128 paediatric T-ALL after haplo-HSCT from 2642 consecutive ALL patients between January 2010 and June 2022.

PROP1 is critical for autophagy and parasite viability during chronic infection.

Unlabelled: Macroautophagy is an important cellular process involving lysosomal degradation of cytoplasmic components, facilitated by autophagy-related proteins. In the protozoan parasite , autophagy has been demonstrated to play a key role in adapting to stress and the persistence of chronic infection. Despite limited knowledge about the core autophagy machinery in , two PROPPIN family proteins (TgPROP1 and TgPROP2) have been identified with homology to Atg18/WIPI.

Survival outcomes between haploidentical stem cell transplantation and chemotherapy for blastic plasmacytoid dendritic cell neoplasm.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and rare hematological malignancy with poor clinical outcomes. Stem cell transplantation helps to achieve long-term survival in adults. However, the benefit of haploidentical stem cell transplantation (HID-SCT) versus chemotherapy is unclear with BPDCN.

Macrofocal multiple myeloma in the era of novel agents in China.

Background: Macrofocal multiple myeloma (MFMM) is characterized by clonal plasma cells comprising less than 20% of the bone marrow, multiple lytic bone lesions, and the absence of anemia, renal insufficiency, and hypercalcemia. This subtype of multiple myeloma (MM) has a relatively low incidence. Prognostic staging and cytogenetic guidance for MFMM are often insufficient due to the low tumor burden in the bone marrow.

A humanized anti-b7h3×4-1BB bispecific antibody exerts potent antitumour effects through the activation of innate and adaptive immunity.

Agonistic monoclonal antibodies targeting 4-1BB have shown much preclinical promise, but their clinical development has been limited by obvious toxicity or unremarkable efficacy. Here, we generated two humanized anti-B7H3 × 4-1BB bsAbs (HK056-001/002) by fusing an anti-4-1BB scFv to the C-terminus of an anti-B7H3 with an intact Fc fragment from human IgG1 or IgG4. The two bsAbs were able to stimulate the 4-1BB signaling pathway, which was strictly dependent on B7H3 expression.

Clinical features and prognostic nomogram for therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

Therapy-related acute myeloid leukemia (t-AML), which develops after cytotoxic therapy, has a poorer prognosis. Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potential cure, its efficacy varies among patients. In this retrospective study, we analyzed 154 patients with t-AML who underwent hematopoietic stem cell transplantation (HSCT) at our institution to determine their clinical characteristics and develop a prognostic nomogram.